Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances

Oncology products

Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes oncology products such as Alimta, Cyramza, Erbitux, Lartruvo, and Verzenio.

In the second quarter, its revenue was driven by strong performances of Alimta, Cyramza, Erbitux, and other drugs.

Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances

The chart above shows revenues for key oncology products since the first quarter of 2017.

Alimta

Alimta is a blockbuster chemotherapy drug. It reported a 4% YoY rise in revenue to $555.9 million in the second quarter compared to revenue of $532.9 million in the second quarter of 2017. The growth included a 3% increase in US sales and a 6% increase in international sales during the quarter.

Cyramza

Cyramza reported a 17% rise in YoY revenue to $218.8 million in the second quarter compared to revenue of $186.3 million in the second quarter of 2017 driven by an increase in global sales. Its US sales rose 10%, and its international sales rose 22% during the quarter.

Erbitux

Erbitux is an oncology drug for the treatment of metastatic colorectal cancer and head and neck cancer. Erbitux reported a 5% rise in YoY revenue to $166.4 million in the second quarter compared to $186.3 million in the second quarter of 2017 driven by strong sales in US markets and nearly flat revenue from international sales.

Lartruvo

Lartruvo is a drug that’s been approved for the treatment of advanced soft tissue sarcoma. Lartruvo reported a 69% rise in revenue to ~$79.9 million in the second quarter compared to revenue of $47.4 million in the second quarter of 2017. Its US sales were $51 million, and its international sales were $29 million in the quarter.

The iShares US Healthcare ETF (IYH) holds 2.6% of its total investments in Eli Lilly, 2.6% in Bristol-Myers Squibb (BMY), 4.8% in Merck & Co. (MRK), and 3.4% in Amgen (AMGN).